Nuo Therapeutics, Inc. (OTCPK: AURX)
Health Care · Biotechnology · US
$1.30
+4.00% today · -48.0% 1Y
Nuo Therapeutics, Inc. (OTCPK: AURX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $62.96M and employs 10 people.
Over the last twelve months the share price has lost 48.0%, trading between 0.77 and 2.92.
Tweenvest scores Nuo Therapeutics, Inc. across four factors: quality 26/100, value 72/100. Its strongest factor is value.
AURX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $62.96M
- Revenue (TTM)
- $5.20M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- -881.13
- 52-week high
- $2.92
- 52-week low
- $0.77
- Avg volume (3M)
- —
- Shares outstanding
- 48.43M
- Employees
- 10
- Next earnings
- —
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
- ISIN
- US67059V2097
- Founded
- 1998
- Listed since
- Oct 24, 2017
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| iNtRON Biotechnology, Inc.KOSDAQ: A048530 | $64.53M | ₩2,785.00 | -2.11% |
| Fortress Biotech, Inc.NasdaqCM: FBIO | $64.37M | $1.93 | -3.02% |
| Oncolytics Biotech Inc.NasdaqCM: ONCY | $63.51M | $0.50 | -10.57% |
| EyeGene Inc.KOSDAQ: A185490 | $63.26M | ₩1,951.00 | +4.33% |
| OS Therapies IncorporatedNYSEAM: OSTX | $60.89M | $1.32 | -18.52% |
| Pharos iBio Co., Ltd.KOSDAQ: A388870 | $60.30M | ₩6,210.00 | -3.12% |
| Hemogenyx Pharmaceuticals PlcLSE: HEMO | $59.69M | £6.58 | -10.48% |
| Gossamer Bio, Inc.NasdaqGS: GOSS | $58.75M | $9.61 | +1.53% |
Figures last refreshed Oct 18, 2026.